pa旗舰厅

84 press releases in total

2022

Sep 6, 2022

Jacobio Receives CDE Approval for KRAS G12C Inhibitor JAB-21822’s Phase II Pivotal Study in China

pa旗舰厅: [More]
Sep 2, 2022

Jacobio Completes First Patient Dosage of CD73 mAb JAB-BX102 in China

pa旗舰厅: [More]
Sep 1, 2022

Jacobio Completes First Dose of IIa Clinical Trial of JAB-21822 on KRAS G12C and STK11 Co-mutation in China

pa旗舰厅: [More]
Aug 23, 2022

Jacobio Announces 2022 Interim Results

pa旗舰厅: [More]
May 27, 2022

Jacobio will Present Phase I Clinical Data of KRAS G12C Inhibitor JAB-21822 at the 2022 ASCO Annual Meeting

pa旗舰厅: [More]
Mar 28, 2022

Jacobio Receives IND Approval for CD73 mAb JAB-BX102 from China CDE

pa旗舰厅: [More]
Mar 23, 2022

Jacobio Announces Annual Results of 2021, R&D Investment Increases 83%

pa旗舰厅: [More]
Feb 24, 2022

Jacobio JAB-21822 in Combination with Cetuximab Completes First Dose of Colorectal Cancer Patient in China

pa旗舰厅: [More]
Jan 17, 2022

Jacobio Receives IND Approval for Aurora A Inhibitor JAB-2485 from FDA

pa旗舰厅: [More]

2021

2020

Dec 1, 2020

Jacobio Announces First Patient Enrolled in Phase I Clinical Trial of BET Inhibitor JAB-8263

pa旗舰厅: [More]
Jun 1, 2020

Pages